Santa Cruz Biotechnology

Executive Summary

Santa Cruz Biotechnology (SCBT) is a privately held, U.S.-based leader in life science research reagents, primarily known for its extensive portfolio of over 100,000 primary antibodies, along with CRISPR/Cas9 gene editing tools, RNAi reagents, and laboratory chemicals. Founded in 1991 and headquartered in Dallas, Texas, the company has established a strong reputation through its products' frequent citation in peer-reviewed publications—over 460,000 to date. SCBT serves a broad customer base including academic institutions, pharmaceutical companies, and biotechnology firms worldwide. As a private entity, it does not disclose financials, but its market position suggests significant recurring revenue from consumables in the research market, which is estimated at over $20 billion globally. The company faces competition from larger suppliers like Thermo Fisher, Abcam, and Bio-Rad, but retains a loyal following due to its broad catalog, competitive pricing, and reliable supply chain.

Upcoming Catalysts (preview)

• Q3 2026Expansion of CRISPR and gene editing product portfolio70% success
• Q2 2026Launch of novel monoclonal antibodies for cancer immunotherapy targets60% success
• TBDStrategic partnership with major research institution for antibody validation50% success